Tango Therapeutics stockholders elect two Class II directors and ratify PwC as auditor

Tango Therapeutics, Inc.

Malte Peters, M.D. elected with 75,943,817 votes for, 3,532,483 withheld (5,145,731 broker non-votes).
Mace Rothenberg, M.D. elected with 76,746,614 votes for, 2,729,682 withheld (5,145,731 broker non-votes).
Ratification of PricewaterhouseCoopers as auditor: 84,619,141 for, 2,888 against, 2 abstain.
Quorum of 95.93% (84,622,031 of 88,209,964 shares) present at virtual annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tango Therapeutics, Inc. shareholders approved Election of two Class II director nominees to the Board of Directors at the 2023-06-06 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Malte Peters, M.D. 75,943,817 3,532,483 5,145,731 Mace Rothenberg, M.D. 76,746,614 2,729,682 5,145,731

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tango Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-06

Exact text from the filing

The results of the ratification were as follows: FOR AGAINST ABSTAIN 84,619,141 2,888 2

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-162609

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.